AU2019356940A1 - Uses of modified RNA encoding retinaldehyde dehydrogenase - Google Patents

Uses of modified RNA encoding retinaldehyde dehydrogenase Download PDF

Info

Publication number
AU2019356940A1
AU2019356940A1 AU2019356940A AU2019356940A AU2019356940A1 AU 2019356940 A1 AU2019356940 A1 AU 2019356940A1 AU 2019356940 A AU2019356940 A AU 2019356940A AU 2019356940 A AU2019356940 A AU 2019356940A AU 2019356940 A1 AU2019356940 A1 AU 2019356940A1
Authority
AU
Australia
Prior art keywords
virus
vaccine
protein
raldh
species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019356940A
Other languages
English (en)
Inventor
Bruno RAPOSO
Ulrich H. Von Andrian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of AU2019356940A1 publication Critical patent/AU2019356940A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01036—Retinal dehydrogenase (1.2.1.36)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mycology (AREA)
AU2019356940A 2018-10-10 2019-10-10 Uses of modified RNA encoding retinaldehyde dehydrogenase Abandoned AU2019356940A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743943P 2018-10-10 2018-10-10
US62/743,943 2018-10-10
PCT/US2019/055543 WO2020077045A1 (en) 2018-10-10 2019-10-10 Uses of modified rna encoding retinaldehyde dehydrogenase

Publications (1)

Publication Number Publication Date
AU2019356940A1 true AU2019356940A1 (en) 2021-05-13

Family

ID=70164700

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019356940A Abandoned AU2019356940A1 (en) 2018-10-10 2019-10-10 Uses of modified RNA encoding retinaldehyde dehydrogenase

Country Status (6)

Country Link
US (2) US20210338709A1 (https=)
EP (1) EP3863646A4 (https=)
JP (1) JP2022512686A (https=)
AU (1) AU2019356940A1 (https=)
CA (1) CA3115522A1 (https=)
WO (1) WO2020077045A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240124532A1 (en) * 2021-01-29 2024-04-18 Institut National De La Santé Et De La Recherche Médicale (Inserm) Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060263340A1 (en) * 2005-04-29 2006-11-23 Andrian Ulrich H V Treating gastrointestinal diseases with modulators of retinoic acid
WO2013036914A1 (en) * 2011-09-08 2013-03-14 University Of Florida Research Foundation, Inc. Materials and methods for modulating immune responses
US20160051669A1 (en) * 2014-08-21 2016-02-25 Georgia Regents University Research Institute, Inc. Compositions and methods for selectively modulating tregs
US10238741B2 (en) * 2014-10-10 2019-03-26 The Trustees Of Columbia University In The City Of New York Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof
EP4523756A3 (en) * 2015-02-13 2025-05-28 Transgene Immunotherapeutic vaccine and antibody combination therapy
EP3308800B1 (en) * 2015-06-10 2021-08-25 The University of Tokyo Adjuvant for vaccines, vaccine, and immunity induction method
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein

Also Published As

Publication number Publication date
US20210338709A1 (en) 2021-11-04
US20250339458A1 (en) 2025-11-06
JP2022512686A (ja) 2022-02-07
CA3115522A1 (en) 2020-04-16
WO2020077045A1 (en) 2020-04-16
EP3863646A1 (en) 2021-08-18
EP3863646A4 (en) 2022-09-28

Similar Documents

Publication Publication Date Title
CN108430456B (zh) 癌症疫苗
JP7139307B2 (ja) Ｒｎａの投与のための配合物
JP7668111B2 (ja) Ｒｎａの投与のための配合物
JP2019517782A (ja) 一本鎖ｒｎａを提供する方法
US20250339458A1 (en) Uses of modified rna encoding retinaldehyde dehydrogenase
JP2025503994A (ja) コロナウイルスワクチン
US20260062716A1 (en) Lipid nanoparticle (lnp) composition or formulation for nucleic acid therapeutics
CN119968210A (zh) 用于预防或治疗结核病的rna
JP2023175686A (ja) ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用
JP2024517642A (ja) ウイルスワクチン
US11633473B2 (en) Stimulator of Interferon Genes (STING) ligands and uses thereof
CN117460827A (zh) 狂犬病核酸疫苗
JP2024522179A (ja) 免疫エフェクタ細胞の活性化および標的化のための薬剤および方法
AU2012229234B2 (en) Vaccine formulation of mannose coated peptide particles
US20250041278A1 (en) Tlr8 agonist for modulating immune response
US20250000971A1 (en) Tlr4 agonist for modulating immune response
Gómez-Aguado 3.2 Nucleic acid delivery systems
HK40102659A (zh) 病毒疫苗
WO2026082899A2 (en) Rna for preventing or treating tuberculosis
CN118176209A (zh) 涉及用于抗原疫苗接种的非免疫原性rna和pd-1轴结合拮抗剂的治疗
WO2024196771A2 (en) Lipid gb3 as adjuvant for vaccination